Calibre What Science Can Do

This website contains promotional content about AstraZeneca Medications. This website is intended for healthcare professionals involved in the Acute Coronary Syndrome care pathway, such as hospital specialists from cardiology and cardiology-related departments, including A&E and elderly care, as well as GPs with a specific interest in cardiology, nurses, pharmacists and payers with budget responsibilities in cardiology.

Hot topics

January 2018 - New!

Real world implementation of dual anti-platelet therapy (DAPT) in high-risk, post-myocardial infarction (MI) patients: Where are we now?
Professor Robert Storey

Professor Robert Storey

Professor Robert Storey is a professor of cardiology at the University of Sheffield. He is also Academic Director and an honorary consultant cardiologist for the Cardiology and Cardiothoracic Surgery Directorate at Sheffield Teaching Hospitals NHS Foundation Trust. He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention.

Professor Storey served as a member of the executive committees for the DISPERSE2, PLATO and PEGASUS-TIMI 54 studies, leading the platelet function sub-studies for these trials and of the steering committees for the TRA-CER, EPICOR and ATLANTIC studies. He is currently a member of the steering committees for the COMPLETE, RAPID CTCA, SENIOR RITA and AUGUSTUS studies. He has been the head of a thrombosis research group at the University of Sheffield since 2002. 

Professor Storey was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012–2014 and has been a task force member for several ESC guidelines on non-ST-elevation acute coronary syndromes (2011 and 2015) and dyslipidaemias (2011).

Long-term dual anti-platelet therapy (DAPT) in high-risk, post myocardial infarction (MI) patients: Where are we now?
Professor Philippe Gabriel Steg

Professor Philippe Gabriel Steg

Dr Philippe Gabriel Steg is a professor of cardiology at Université Paris Diderot and the National Heart and Lung Institute of Imperial College London. He is also an interventional cardiologist and Chief of the Cardiology Department at Hôpital Bichat, Assistance Publique-Hôpitaux de Paris.

Dr Steg participates in the leadership of many trials in coronary artery disease and is currently Chair/co-Chair or principal investigator of several large clinical trials or registries such as ODYSSEY Outcomes, CLARIFY, THEMIS, REALITY, and SCORED. He is Chair of the FACT: French Alliance for Cardiovascular Clinical Trials academic research network, was co-Chair of the REACH registry and the GRACE registry publication committee, and participated in numerous data monitoring committees or clinical events committees.

Dr Steg is co-Coordinator of the Département Hospitalo-Universitaire FIRE affiliated with INSERM, Université Paris Diderot and Assistance Publique – Hôpitaux de Paris, and Coordinator of the iVASC research consortium. He has authored over 1,000 articles in international peer-reviewed journals, is Associate Editor for Circulation and on the editorial board for the European Heart Journal. He received the silver medal of the European Society of Cardiology (ESC) in 2011 and co-chaired the ESC task force in charge of the 2012 Guidelines for management of ST-segment elevation myocardial infarction.

May 2017

The atherothrombotic story
Professor Azfar Zaman

Azfar Zaman is a professor of clinical cardiology at Freeman Hospital and Newcastle University, Newcastle upon Tyne and Head of Coronary Intervention and Director of the cardiac catheter laboratories at Freeman Hospital. He completed his postgraduate training in cardiology at regional centres in Leeds, London and Cardiff, following which, he was awarded a Fulbright Scholarship and a 2-year British Heart Foundation International Fellowship to study vascular biology at Mount Sinai Medical Center, New York.

As Clinical Director for Cardiovascular Research, and with interests in clinical research, atherothrombosis in diabetes and clinical trials, Professor Zaman has been awarded research grants from the British Heart Foundation, Diabetes Wellness Research Foundation and the National Institute for Health Research. He currently leads a team of 16 individuals conducting clinical trials and research in cardiology and has built an impressive publication record with Professor Azfar Zaman over 100 peer-reviewed publications.

Platelet testing following coronary stenting—is the debate over?
Professor Gilles Montalescot

Gilles Montalescot is a professor of cardiology at the Pitié-Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing interventional cardiologist and has extensive experience in basic and clinical research. Professor Montalescot is Director of the INSERM research unit UMRS_1166 on thrombosis and Chairman of the ACTION study group, an academic research organisation based at Pitié-Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery Disease guidelines of the European Society of Cardiology.

Professor Montalescot has received several awards in his country including the J. Valade prize from the Fondation de France and the J. Escalle award from the National Academy of Medicine. Professor Montalescot is a member of several editorial boards and has published over 400 peer-reviewed original articles in journals such as NEJM, JAMA, The Lancet and Circulation. Internationally, Professor Montalescot has also been an invited plenary session speaker at all the major congresses such as the European Society of Cardiology, the American College of Cardiology and the American Heart Association.